drugset / Trial / NCT01590199

Evaluate Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs

NCT01590199

Phase 1 Completed 18 enrolled Novartis Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will evaluate long-term safety and tolerability of pasireotide LAR in combination with everolimus in advanced metastatic NET patients, who who have not progressed during 12 months of combination therapy with pasireotide LAR and everolimus

Timeline

Start
2012-05-18
Primary completion
2018-09-11
Completion
2018-09-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Everolimus Small molecule
Subject Pasireotide Other / unclassified